Table II.
Group | No. patients | CR | PR | SD | PD |
---|---|---|---|---|---|
Gemcitabine/docetaxel | 21 | 0 | 2 | 4 | 15 |
Pemetrexed/cisplatin | 18 | 0 | 1 | 5 | 12 |
Patients were classified according to the Response Evaluation Criteria in Solid Tumors: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.